Thursday Nov 13 | The South Mississippi Sun Herald
Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month...
Debiopharm Group , a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, today announced that the New Drug Application for the 6 month ...
Watson's departure from Putnam still set for 2010
Plans by Putnam County's second-largest private employer to relocate remain on track despite some who are interpreting a heightened workload as a possibly hopeful sign.
Quarterly earnings double for Watson
Corona-based specialty drug maker Watson Pharmaceuticals this morning reported earnings of $71.1 million for its third quarter ending Sept.
Fitch Affirms Watson Pharmaceuticals' IDR at 'BBB-'; Outlook Stable
Fitch Affirms Watson Pharmaceuticals' IDR at 'BBB-'; Outlook Stable Comtex CHICAGO, Oct 27, 2008 ----Fitch has affirmed Watson Pharmaceuticals, Inc.'s ratings as follows: --Issuer Default Rating at 'BBB-'; ...
Business in the Burbs: Watson Pharma sues Barr over patents
Two drug manufacturers are battling in court over a skin patch used to treat bladder problems.
Watson Files Lawsuit Against Barr for OXYTROL Patent Infringement
Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today announced that its subsidiary Watson Laboratories, Inc.
Watson Wins U.S. Approval for Rapaflo, New Treatment for Enlarged Prostate
Watson Pharmaceuticals Inc. won U.S. approval to sell a prostate enlargement treatment as the drugmaker expands beyond manufacturing generic medicines.
FDA Approves Silodosin for Treatment of Enlarged Prostate
Watson Pharmaceuticals Inc. announced Wednesday evening that FDA had approved the marketing of silodosin, or Rapaflo, to treat the signs and symptoms of benign prostatic hyperplasia.
Watson Pharmaceuticals gets go ahead on prostate drug
The U.S. Food and Drug Administration has given the go ahead to Corona-based Watson Pharmaceuticals Inc.
Watson announces positive data from studies of topical gel for treatment of OAB
The data from the open-label, randomised studies in healthy men and women showed that showering one hour or later, or the application of sunscreen 30 minutes before or after OTG application did not ...
Kissei Pharma Rises After U.S. Regulators Approves Prostate Pill for Sale
Kissei Pharmaceutical Co. , a Japanese drugmaker, rose the most in more than eight years in Tokyo trading after U.S. regulators approved one of its prostate treatments for sale.
Watson Receives Us Fda Approval for Rapaflo(TM) (silodosin) for the...
Watson Receives US FDA Approval for RAPAFLO for the Treatment of Benign Prostatic Hyperplasia Comtex CORONA, Calif., Oct 08, 2008 /PRNewswire-FirstCall via COMTEX/ ----Watson Pharmaceuticals, Inc.
Watson Announces Positive Data for Its Investigational Oxybutynin...
Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that investigators presented clinical pharmacokinetic data on oxybutynin chloride topical gel , its investigational ...
The South Mississippi Sun Herald
Watson Notified of OXYTROL(R) Patent Challenge
Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today confirmed the receipt of a Paragraph IV Certification Notice Letter relating to an Abbreviated New Drug Application submitted to ...
5 Stocks Approaching Greatness
Some companies are obviously great investments -- in hindsight. Yet for every stock out there screaming " buy me ," others simply give us a nudge and a nod.
Your browser's security settings are preventing some features from appearing. See instructions for fixing the problem.
Extended Look at an Extended-Release Drug
Negative publicity is something most companies should avoid. But if you are a pharmaceutical company and the negative publicity is about one of your drugs, well, that can be a problem.
Ranbaxy's Troubles Won't Help Competitors
When a company stumbles, it's often a great opportunity for competitors to step in and fill the void.
David Hsia, Ph.D. Joins Kinex Pharmaceuticals' Board of Directors
Kinex Pharmaceuticals announced that David Hsia, Ph.D. has been appointed to the Company's Board of Directors.
Watson Announces Change to Presentation Time at the Morgan Stanley...
Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today announced a change to its presentation time at the Morgan Stanley Global Healthcare Unplugged Conference that is being held on ...